Argent Biopharma Ltd (fra:H5O0) Share Price

Company Profile

Business description
Argent Biopharma Ltd is a revenue-generating, clinical-stage biopharmaceutical company focused on the development and commercialization of nano-engineered therapeutics targeting neurological and immunemediated disorders. Its assets, CannEpil and CimetrA, are for drug-resistant epilepsy and inflammatory conditions, respectively. The company leverages proprietary nano-delivery technologies designed to optimize bioavailability and tissue penetration, including across the blood-brain barrier and pulmonary interfaces. The company operates in a single segment. Geographically, it operates in Malta, Slovenia, UK, and Australia, with the majority of revenue deriving from Slovenia.
Contact
295 Rokeby Road
Suite 1
SubiacoWA6008
AUS
T: +61 865552950
E: [email protected]
https://www.argentbiopharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
Employees

Recommended

Fear outweighs fundamentals as ASX share reaffirms outlook.

Nathan Zaia | 29 October 2026

We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.

Eric Compton, CFA | 29 October 2026

We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.

Malik Ahmed Khan, CFA | 29 October 2026

Index	Last price	Change	% Change
All Ordinaries	9,025.40	12.80	0.14%
CAC 40	7,969.42	0.58	-0.01%
DAX 40	25,818.21	221.47	-0.85%
Dow JONES (US)	51,770.31	572.25	-1.09%
FTSE 100	10,729.78	7.71	0.07%
HKSE	23,294.42	335.77	1.46%
NASDAQ	25,437.00	747.73	-2.86%
Nikkei 225	63,290.11	1,369.36	-2.12%
NZX 50 Index	13,797.00	86.83	0.63%
S&P 500	7,580.07	140.32	-1.82%
S&P/ASX 200	8,908.10	16.30	0.18%
SSE Composite Index	3,599.02	52.42	-1.44%